Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TQB2618 + penpulimab + anlotinib
- Development stage
- Unknown
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination therapy comprising **TQB2618** (a TIM-3 blocking monoclonal antibody), **penpulimab** (an anti-PD-1 monoclonal antibody), and **anlotinib** (a small molecule multi-targeted tyrosine kinase inhibitor) under clinical investigation for the treatment of advanced or metastatic nasopharyngeal carcinoma. TQB2618 is designed to block T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3), thereby potentially enhancing immune response against tumors. Penpulimab blocks the PD-1 checkpoint, enhancing immune-mediated tumor cell killing, while anlotinib targets several receptor tyrosine kinases including VEGFR, FGFR, PDGFR, and c-Kit, inhibiting tumor angiogenesis and proliferation[4][6].
- Other names
- TQB2618 + penpulimab + anlotinibTQB2618 injection combined with penpulimab injection and anlotinib hydrochloride capsulesTQB-2618 injection combined with penpulimab injection and anlotinib hydrochloride capsulesTQB 2618 injection combined with penpulimab injection and anlotinib hydrochloride capsules
02
Targets
HAVCR2 (T cell immunoglobulin and mucin domain-containing protein 3)PDGFRA (Platelet-derived growth factor receptor alpha)KIT (c-KIT proto-oncogene receptor tyrosine kinase)FGFR3 (Fibroblast growth factor receptor 3)PDCD1 (Programmed cell death protein 1 receptor)VEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on TQB2618 + penpulimab + anlotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TQB2618 + penpulimab + anlotinib.